July 6, 2023
Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Year
2023
Assets in this page
Download assets
- pdf file
Current Report ESPI 34/2023
Download